HomeBUSINESS
BUSINESS

Sumitomo Dainippon In-Licenses Diabetes Med from France’s Poxel
(Nov.1.2017)

Sumitomo Dainippon Pharma has grabbed development and commercialization rights in 13 Asian markets including Japan for imeglimin, an investigational type 2 diabetes drug being developed by France’s Poxel, the two companies said on October 30 ...
(LOG IN FOR FULL STORY)

News Calendar